Stryker Sells U.S. Spinal Implants Business

Stryker to Sell its U.S. Spinal Implants Business
“We believe that the spinal implants business, with its comprehensive portfolio and strong sales channel, will thrive as an independent company," said Kevin A. Lobo, Chair and Chief Executive Officer, Stryker. "With dedicated resources and a focused strategy, the business will be well positioned to succeed as part of Viscogliosi Brothers.”
Stryker to spin off spinal implant business, as Viscogliosi Brothers-owned VB Spine
Stryker is selling off its spine implant business—starting with a plan to spin off its U.S. operations before moving on to divest its international enterprises in the months to come. | Stryker is selling off its spine implant business—starting with a plan to spin off its U.
Stryker Stock Falls on Deal to Sell Its U.S. Spinal Implants Business
Stryker Corporation SYK recently announced a definitive agreement to sell its U.S. spinal implants business to Viscogliosi Brothers, LLC, a family-owned investment firm specializing in the neuro-musculoskeletal space,
Stryker to Sell Spinal Implants Business to Viscogliosi Brothers
Stryker has agreed to sell its U.S. spinal implants business to Viscogliosi Brothers to create a newly formed company called VB Spine. The medical technology company said Tuesday the New York City-based Viscogliosi Brothers specializes in neuro-musculoskeletal treatments.
Stryker beats Q4 estimates, sells spinal implants biz
Stryker Corp reported fourth-quarter earnings that beat Wall Street estimates, with earnings of $4.01 per share, ahead of analysts’ expectations of $3.87. Revenue rose to $6.4 billion, slightly ahead of the consensus estimate of $6.
Stryker to sell spinal implants business
Stryker reported goodwill and other impairments of $818 million related to the spine business in the fourth quarter.
Stryker Corp. stock underperforms Tuesday when compared to competitors
The stock's fall snapped a three-day winning streak.
bovnews4h
Stock Shock: The Unpredictable Rise and Fall of SYK—What’s Driving the Drama?
On Tuesday, Stryker Corp (SYK) stock saw a decline, ending the day at $395.15 which represents a decrease of $-4.75 or -1.19% from the prior close of $399.9. The stock opened at $400.61 and touched a ...
Stryker forecasts 2025 profit above estimates on robust demand for surgical devices
Stryker beat Wall Street estimates for fourth-quarter profit and forecast 2025 earnings largely above expectations on Tuesday, fueled by strong demand for its medical and surgical devices. Medical and ...
Buy Rating for Stryker: Robust Performance and Strategic Growth Drivers
Analyst Patrick Wood from Morgan Stanley maintained a Buy rating on Stryker (SYK – Research Report) and keeping the price target at ...
Becker's Spine Review1h
Stryker's shoulder robot earns FDA approval
Stryker's Mako shoulder robot earned FDA approval in December, Jason Beach, vice president of finance and investor relations, said in a Jan. 28 earnings call.
Stryker's Strategic Moves Impress Analysts, Spine Implant Sale and NARI Deal Set to Drive Future Growth
Wall Street analysts upgraded Stryker Corp (NYSE: SYK) after its Q4 report beat expectations, with strong sales and earnings growth projected for 2025.
Stryker’s Strategic Moves and Strong Performance Drive Buy Rating
In a report released today, Michael Matson from Needham reiterated a Buy rating on Stryker (SYK – Research Report), with a price target of ...